The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Learn more about whether Roivant Sciences Ltd. or Travere Therapeutics, Inc. is a better investment based on AAII's A+ ...

Learn more about whether Protagonist Therapeutics, Inc. or Travere Therapeutics, Inc. is a better investment based on AAII's ...

Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGSNet product sales of FILSPARI ...

oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the ...

Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) gapped down prior to trading on Friday after the company announced weaker than expected quarterly earnings. The stock had ...

After hours: February 21 at 7:55:48 PM EST Loading Chart for CPHI ...

Nephrolithiasis is an increasingly prevalent disorder in the elderly that is associated with multiple comorbid conditions such as hypertension, coronary artery disease, diabetes and CKD. Care of ...

Travere Therapeutics (TVTX) reported $74.79 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 66%. EPS of -$0.73 for the same period compares to -$1 ...